Genmab — Februar 2024
-
If a certain employee has a contract where it states that, for example, 10% of his total pay will be in the form of shares, he will get more shares if the share price is lower. Eg employee gets 10.000 dk from every 100.000 of salary in shares; in Feb 23 he got +- 10.000/2700 = 3.7 shares ; in Feb 24 het gets 10.000/2000 = 5 shares.
-
Still lacking strategic rationale - why pay 2x for an already fixed royalty stream?
-
Ownership structure in GEN would all but guarantee an easy buy-out - but dara and the heavy and unproductive cost base are effective poison pills for any investor
-
indeed I do. Hexacd38 is a red herring
-
JW is perhaps playing the game by telling investors that Genmab could be without dara (anti cd38) royalty in the 30’th - either is he saying to JNJ ”we can do it without you” or he is preparing investors on a takeout by JNJ because many cant see value in Genmab after dara. Or perhaps he realised that the opt.in. will not take place. Or none of it
-
...or perhaps he is feeling the suffocating feeling from a drowning warrant program
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind